Capacity Bio is a private biotech company developing a first-in-class mitophagy therapeutic platform along with the most advanced analytical toolkit to characterize mitochondria. The team has discovered a novel cellular target that induces mitochondrial turnover resulting in improved mitochondrial quality. Capacity's pipeline includes opportunities in neurodegenerative and autoimmune disorders, myopathies, and genetic orphan indications. Capacity Bio is headquartered in Los Angeles, CA. Remiges is a founding investor.